Ryan Deschner
Stock Analyst at Raymond James
(4.40)
# 325
Out of 4,900 analysts
11
Total ratings
60%
Success rate
29.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVRD Tvardi Therapeutics | Initiates: Outperform | $62 | $27.94 | +121.90% | 1 | Jul 14, 2025 | |
| APLS Apellis Pharmaceuticals | Downgrades: Outperform | $75 → $52 | $19.36 | +168.60% | 1 | May 9, 2025 | |
| LQDA Liquidia | Maintains: Strong Buy | $27 → $29 | $14.27 | +103.22% | 3 | May 9, 2025 | |
| TRVI Trevi Therapeutics | Upgrades: Strong Buy | $9 → $29 | $6.96 | +316.67% | 2 | Mar 10, 2025 | |
| ARDX Ardelyx | Reiterates: Strong Buy | $15 → $13 | $4.59 | +183.22% | 1 | Feb 21, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $17.41 | +60.83% | 3 | Jan 14, 2025 |
Tvardi Therapeutics
Jul 14, 2025
Initiates: Outperform
Price Target: $62
Current: $27.94
Upside: +121.90%
Apellis Pharmaceuticals
May 9, 2025
Downgrades: Outperform
Price Target: $75 → $52
Current: $19.36
Upside: +168.60%
Liquidia
May 9, 2025
Maintains: Strong Buy
Price Target: $27 → $29
Current: $14.27
Upside: +103.22%
Trevi Therapeutics
Mar 10, 2025
Upgrades: Strong Buy
Price Target: $9 → $29
Current: $6.96
Upside: +316.67%
Ardelyx
Feb 21, 2025
Reiterates: Strong Buy
Price Target: $15 → $13
Current: $4.59
Upside: +183.22%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $17.41
Upside: +60.83%